welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers
study id #: NCT01540604
condition: Duchenne Muscular Dystrophy , Becker Muscular Dystrophy
This is an investigation of the efficacy and safety of CRD007 in Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD) and symptomatic carriers.
mechanism of action: Non-steroidal agent to decrease inflammation
last updated: November 22, 2018
phase of development: Phase 2
Documented diagnosis of dystrophinopathy
Severe functional impairment
Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMDThe main objective of this study is to e...
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular DystrophyThe primary objective of this study is t...
Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular DystrophyThe primary objective of this study is t...
Oral Ifetroban in Subjects With Duchenne Muscular DystrophyDuchenne muscular dystrophy (DMD) is a d...
Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, ran...Background: Duchenne muscular dystrophy...
FibroGen Receives Orphan Drug Designation from the U.S. FDA For Pamrevlumab for the Treatment of Duchenne Muscular D...FibroGen, Inc., a leading biopharmaceu...
A phase 2 trial of the safety and pharmacokinetics of ataluren in patients aged 2 to 5 years with nonsense mutation ...Nonsense mutation Duchenne muscular dyst...
Promising new therapy spares muscle loss in Duchenne muscular dystrophyBUFFALO, N.Y. — A promising therapy fo...
Rimeporide: safety, tolerability and pharmacokinetic results from a phase Ib study in DMD boys as well as explorator...In Duchenne muscular dystrophy, impaired...